Literature DB >> 7527006

Inhibition by recombinant human interleukin-6 of the glucagon-dependent induction of phosphoenolpyruvate carboxykinase and of the insulin-dependent induction of glucokinase gene expression in cultured rat hepatocytes: regulation of gene transcription and messenger RNA degradation.

B Christ1, A Nath, P C Heinrich, K Jungermann.   

Abstract

The influence of recombinant human interleukin-6, the major mediator of the inflammatory response in liver, on the glucagon- and insulin-dependent induction of the phosphoenolpyruvate carboxykinase and glucokinase gene, respectively, was monitored on the level of gene transcription, mRNA abundance and enzyme activity in cultured rat hepatocytes. As control markers of the interleukin-6-induced acute-phase response the mRNA levels of the acute phase proteins alpha 2-macroglobulin and beta-fibrinogen were determined. In cultured rat hepatocytes, recombinant human interleukin-6, added simultaneously with glucagon and insulin, lowered the maximal increase in glucagon-induced phosphoenolpyruvate carboxykinase mRNA levels after 2 hr and the maximal increase in glucokinase mRNA levels after 3 hr to about 30%, respectively. It inhibited the glucagon-induced increase in phosphoenolpyruvate carboxykinase gene transcription and phosphoenolpyruvate carboxykinase enzyme activity, as well as the insulin-induced increases in glucokinase gene transcription and glucokinase enzyme activity. Recombinant human interleukin-6 increased the mRNA levels of the acute-phase proteins alpha 2-macroglobulin and beta-fibrinogen gradually over 4 to 6 hr. Recombinant human interleukin-6, added 2 hr after glucagon or 3 hr after insulin at the maximum of the hormone-induced enzyme mRNA levels, almost doubled the decay rate of phosphoenolpyruvate carboxykinase mRNA and glucokinase mRNA. The results show that interleukin-6 induced the expression of inflammatory proteins and simultaneously inhibited the hormone-induced expression of enzymes of intermediary metabolism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527006     DOI: 10.1002/hep.1840200629

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Elevated expression of hormone-regulated rat hepatocyte functions in a new serum-free hepatocyte-stromal cell coculture model.

Authors:  K Ries; P Krause; M Solsbacher; P Schwartz; K Unthan-Fechner; B Christ; P M Markus; I Probst
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-09       Impact factor: 2.416

Review 2.  Interleukin-6 and insulin sensitivity: friend or foe?

Authors:  A L Carey; M A Febbraio
Journal:  Diabetologia       Date:  2004-07-07       Impact factor: 10.122

3.  Trace metal, acute phase and metabolic response to endotoxin in metallothionein-null mice.

Authors:  A M Rofe; J C Philcox; P Coyle
Journal:  Biochem J       Date:  1996-03-15       Impact factor: 3.857

4.  Impairment by interleukin 1 beta and tumour necrosis factor alpha of the glucagon-induced increase in phosphoenolpyruvate carboxykinase gene expression and gluconeogenesis in cultured rat hepatocytes.

Authors:  B Christ; A Nath
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

5.  IL-6 deficiency in mice neither impairs induction of metabolic genes in the liver nor affects blood glucose levels during fasting and moderately intense exercise.

Authors:  L Fritsche; M Hoene; R Lehmann; H Ellingsgaard; A M Hennige; A K Pohl; H U Häring; E D Schleicher; C Weigert
Journal:  Diabetologia       Date:  2010-04-22       Impact factor: 10.122

6.  Impact of interleukin-6 on the glucose metabolic capacity in rat liver.

Authors:  Bianca Lienenlüke; Bruno Christ
Journal:  Histochem Cell Biol       Date:  2007-09-06       Impact factor: 4.304

7.  Effect of insulin levels on the phosphorylation of specific amino acid residues in IRS-1: implications for burn-induced insulin resistance.

Authors:  Xiao-Ming Lu; Victoria F Hamrahi; Ronald G Tompkins; Alan J Fischman
Journal:  Int J Mol Med       Date:  2009-10       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.